Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Management of Behavioral and Psychological Symptoms of Dementia.

Şahin Cankurtaran E.

Noro Psikiyatr Ars. 2014 Dec;51(4):303-312. doi: 10.5152/npa.2014.7405. Epub 2014 Dec 1. Review.

2.

Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series.

Abraha I, Rimland JM, Trotta FM, Dell'Aquila G, Cruz-Jentoft A, Petrovic M, Gudmundsson A, Soiza R, O'Mahony D, Guaita A, Cherubini A.

BMJ Open. 2017 Mar 16;7(3):e012759. doi: 10.1136/bmjopen-2016-012759. Review. Erratum in: BMJ Open. 2017 Jul 17;7(7):e012759corr1.

3.

Optimal nonpharmacological management of agitation in Alzheimer's disease: challenges and solutions.

Millán-Calenti JC, Lorenzo-López L, Alonso-Búa B, de Labra C, González-Abraldes I, Maseda A.

Clin Interv Aging. 2016 Feb 22;11:175-84. doi: 10.2147/CIA.S69484. eCollection 2016. Review.

4.

Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance.

Keogh R, Frost C, Owen G, Daniel RM, Langbehn DR, Leavitt B, Durr A, Roos RA, Landwehrmeyer GB, Reilmann R, Borowsky B, Stout J, Craufurd D, Tabrizi SJ.

PLoS Curr. 2016 Jan 11;8. pii: ecurrents.hd.8060298fac1801b01ccea6acc00f97cb. doi: 10.1371/currents.hd.8060298fac1801b01ccea6acc00f97cb.

5.

Cognitive behavioural treatment for mild Alzheimer's patients and their caregivers (CBTAC): study protocol for a randomized controlled trial.

Forstmeier S, Maercker A, Savaskan E, Roth T.

Trials. 2015 Nov 17;16:526. doi: 10.1186/s13063-015-1043-0.

6.
7.

The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.

Vermeiren Y, Van Dam D, Aerts T, Engelborghs S, Martin JJ, De Deyn PP.

Alzheimers Res Ther. 2015 Feb 11;7(1):7. doi: 10.1186/s13195-014-0090-1. eCollection 2015.

8.

Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design.

Soto M, Andrieu S, Nourhashemi F, Ousset PJ, Ballard C, Robert P, Vellas B, Lyketsos CG, Rosenberg PB.

Int Psychogeriatr. 2014 Sep 16:1-17. [Epub ahead of print]

9.

Psychotropic and psychoactive drugs and hospitalization rates in nursing facility residents.

Cooper JW, Freeman MH, Cook CL, Burfield AH.

Pharm Pract (Granada). 2007 Jul;5(3):140-4.

10.

Cognitive stimulation in patients with dementia: randomized controlled trial.

Mapelli D, Di Rosa E, Nocita R, Sava D.

Dement Geriatr Cogn Dis Extra. 2013 Aug 29;3(1):263-71. doi: 10.1159/000353457. eCollection 2013.

11.

The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease.

Lopez OL, Becker JT, Chang YF, Sweet RA, Aizenstein H, Snitz B, Saxton J, McDade E, Kamboh MI, DeKosky ST, Reynolds CF 3rd, Klunk WE.

Am J Psychiatry. 2013 Sep;170(9):1051-8. doi: 10.1176/appi.ajp.2013.12081046.

12.

Behavior management approach for agitated behavior in Japanese patients with dementia: a pilot study.

Sato J, Nakaaki S, Torii K, Oka M, Negi A, Tatsumi H, Narumoto J, Furukawa TA, Mimura M.

Neuropsychiatr Dis Treat. 2013;9:9-14. doi: 10.2147/NDT.S38943. Epub 2012 Dec 21.

13.

Nonpharmacologic management of behavioral symptoms in dementia.

Gitlin LN, Kales HC, Lyketsos CG.

JAMA. 2012 Nov 21;308(19):2020-9. doi: 10.1001/jama.2012.36918.

14.

Citalopram for agitation in Alzheimer's disease: design and methods.

Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, Pelton G, Frangakis C, Rabins PV, Munro CA, Meinert CL, Devanand DP, Yesavage J, Mintzer JE, Schneider LS, Pollock BG, Lyketsos CG; CitAD Research Group.

Alzheimers Dement. 2012;8(2):121-30. doi: 10.1016/j.jalz.2011.01.007. Epub 2012 Feb 1.

15.

Behavioral and psychological symptoms of dementia and their management.

Kar N.

Indian J Psychiatry. 2009 Jan;51 Suppl 1:S77-86.

16.

Family caregivers of people with dementia.

Brodaty H, Donkin M.

Dialogues Clin Neurosci. 2009;11(2):217-28. Review.

17.

Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease.

Siddique H, Hynan LS, Weiner MF.

J Clin Psychiatry. 2009 Jun;70(6):915-8. doi: 10.4088/JCP.08m04828. Epub 2009 May 5.

18.

Evaluation of a home-based exercise program in the treatment of Alzheimer's disease: the Maximizing Independence in Dementia (MIND) study.

Steinberg M, Leoutsakos JM, Podewils LJ, Lyketsos CG.

Int J Geriatr Psychiatry. 2009 Jul;24(7):680-5. doi: 10.1002/gps.2175.

19.

Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years.

Fillenbaum GG, van Belle G, Morris JC, Mohs RC, Mirra SS, Davis PC, Tariot PN, Silverman JM, Clark CM, Welsh-Bohmer KA, Heyman A.

Alzheimers Dement. 2008 Mar;4(2):96-109. doi: 10.1016/j.jalz.2007.08.005.

20.

Neuropsychiatric symptoms in Alzheimer disease and related disorders: why do treatments work in clinical practice but not in the randomized trials?

Lavretsky H.

Am J Geriatr Psychiatry. 2008 Jul;16(7):523-7. doi: 10.1097/JGP.0b013e318178416c. No abstract available.

Supplemental Content

Support Center